Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
36-Month Open-Label Extension Study of Leuprorelin Acetate in Children with Central Precocious Puberty
2014-004494-16Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Dec 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in central precocious puberty (CPP), sponsored by AbbVie Inc.
02
Drugs
leuprolide
03
Conditions
central precocious puberty (CPP)
Beyond the preview
Go deeper on 2014-004494-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004494-16.